All stock lists
SBC Medical Group Holdings Inco (NASDAQ:SBC)
US · Delayed Price · Currency is USD
Also listed: PTWOIndustrials · Consulting Services
$7.35+$2.01 (+37.64%)
Market cap
$756M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 26, 2022
Website
Insider Score
––Not scored
SBC Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Strong
From SBC’s reported statements · Q3 2026 (trailing 12 months)
Profitability20 / 20
Keeps a healthy share of every dollar it sells.
- Revenue
- $190.4M
- Net income
- $51.9M
- Net margin
- 27.3%
Leverage20 / 20
Little or no net debt.
- Total debt
- $44.0M
- Cash
- $198.4M
- Net debt / EBITDA
- -1.83x
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $273.9M
- Current liabilities
- $74.7M
- Current ratio
- 3.67
Cash generation20 / 20
The business funds itself from operations.
- Operating cash flow
- $102.2M
- Free cash flow
- $99.1M
- FCF margin
- 52.0%
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 102.6M
- Share growth (1y)
- -0.1%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
SBC Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | $58.58 M | $49.19 M | $43.06 M | $39.57 M | $43.35 M | $43.36 M |
| Revenue Growth (YoY) | 35.13 % | 13.44 % | -9.02 % | -10.93 % | -18.33 % | -18.35 % |
| Cost of Revenue | $16.40 M | $13.21 M | $13.02 M | $10.64 M | $13.45 M | $13.35 M |
| Gross Profit | $42.18 M | $35.98 M | $30.04 M | $28.93 M | $29.90 M | $30.01 M |
| SG&A Expense | $15.76 M | $17.02 M | $12.32 M | $18.63 M | $13.95 M | $14.39 M |
| R&D Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expenses | $15.76 M | $17.02 M | $12.32 M | $16.08 M | $14.02 M | $15.46 M |
| Operating Income | $26.42 M | $18.96 M | $17.72 M | $12.85 M | $15.88 M | $14.55 M |
| Pretax Income | $25.79 M | $19.55 M | $18.86 M | $18.57 M | $18.51 M | $13.54 M |
| Tax Provision | $9.38 M | $7.82 M | $7.53 M | $4.29 M | $5.67 M | $11.10 M |
| Net Income | $15.69 M | $10.69 M | $11.31 M | $14.20 M | $12.82 M | $2.46 M |
| EPS (Basic) | $0.15 | $0.10 | $0.11 | $0.14 | $0.12 | $0.02 |
| EPS (Diluted) | $0.15 | $0.10 | $0.11 | $0.14 | $0.12 | $0.02 |
| Shares Outstanding | 102.58 M | 102.58 M | 102.58 M | 102.58 M | 102.64 M | 103.51 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.